Purpose Sotatercept, an activin signalling inhibitor approved in March 2024 for pulmonary arterial hypertension (PAH), ...
Q25 Gross Profit +12% to $114 million; FY 2025 Gross Profit +14% to $446 million4Q25 Income from Operations +9% to $22 million; Adjusted EBITDA ...
Fidelity Emerging Markets Ltd - Final Results for the year ended 30 June 2025 PR Newswire LONDON, United Kingdom, October 06 FIDELITY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback